This pipeline analysis report offers detailed insights into the clinical trials landscape of the stem cell therapy for multiple sclerosis including molecules at different development stages. Moreover, the report also offers information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration.
Overview of the stem cell therapy for multiple sclerosis
Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision, and tingling. At present, therapies available for multiple sclerosis majorly focuses on slowing the progression of the disease, whereas, symptomatic interventions determine the management of the disease. Technavio's market research analysts have predicted that with the introduction of mesenchymal stem cells therapy as one of the most promising investigational approach to treat multiple sclerosis, the global multiple sclerosis market will witness growth in the forthcoming years. it has been observed that the American cryostem and celgene cellular therapeutics have their stem cell therapy candidates for the treatment of multiple sclerosis in phase I stage of development.
According to this pipeline analysis report, most of the companies have not specified the type of multiple sclerosis their drugs are being developed for. One of the Tier 1 companies Celgene cellular therapeutics, is developing PDA-001 for RRMS as well as SPMS.
This pipeline analysis report provides a comprehensive analysis of the companies that are actively involved in the development of stem cell therapy molecules for the treatment of multiple sclerosis. In addition to offering information on the various stages of molecules developed for different indications, this pipeline analysis report also provides information about the stem cell therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are -
Celgene Cellular Therapeutics
Cell Cure Neurosciences
Therapeutic assessment of the stem cell therapy for multiple sclerosis by route of administration
According to our research experts, majority of stem cell therapy candidates that are currently in the pipeline are being developed as intravenous drugs. However, the RoA for several drugs that are in the early development stages are not disclosed by companies.
Key questions answered in the report include
What are the stem cell molecules in the various development stages for multiple sclerosis?
What are the companies that are currently involved in the development of stem cell therapy molecules for multiple sclerosis?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule.
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Single User License - Only one user can access this report at time, users are not allowed to take a print out of the report PDF.
Enterprise User License - This license will allow the entire company (Interface) to access the unlocked PDF version of this report without any restrictions. You can also take the print out if you wish to receive the hard copy version of this report.
Multi User License - This license will be allowing up to five users have access to the product. The report will be emailed to you. The report is sent in PDF format.
Site License - This is a site license, allowing all users within a given geographical location of your organisation access to the product. The report will be emailed to you. The report is sent in PDF format.